HC Wainwright Reiterates Buy Rating for Valneva (NASDAQ:VALN)

Valneva (NASDAQ:VALN)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $17.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 137.10% from the stock’s current price.

Valneva Stock Performance

VALN stock opened at $7.17 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78. The stock has a market cap of $582.64 million, a P/E ratio of -55.15 and a beta of 1.93. The firm has a 50 day simple moving average of $6.34 and a 200 day simple moving average of $5.59. Valneva has a 52 week low of $3.62 and a 52 week high of $9.50.

Valneva (NASDAQ:VALN) last issued its quarterly earnings data on Wednesday, March 19th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.32). The business had revenue of $56.48 million for the quarter, compared to the consensus estimate of $55.64 million. Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. Research analysts anticipate that Valneva will post 0.13 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Valneva

A hedge fund recently bought a new stake in Valneva stock. ABC Arbitrage SA acquired a new stake in shares of Valneva SE (NASDAQ:VALN) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 19,244 shares of the company’s stock, valued at approximately $84,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.